Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Neurocrine Biosciences Inc

NASDAQ: NBIX · Life Sciences · 4 alerts · CIK 914475

Share price
$165.31Close, Nov 16
Market cap
$16.7B
Shares outstanding
101.22MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Neurocrine Biosciences Inc filings on SEC EDGAR ↗

6:52 PM ET Form 4
Insider Selling

Neurocrine Biosciences Insider George J. Morrow Sells $2.34M of Stock

George J. Morrow sold 15,000 shares of Neurocrine Biosciences Inc at $144.98 to $168.53 a share (average $155.73) in 12 transactions, worth $2.34M in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 10,386 (-11.1%).

Value
$2.34M
Shares
15,000
Average price
$155.73
Holding change
-11.1%
Trade date
Oct 30, 2026 to Nov 3, 2026
4:14 PM ET 10-Q
Financial Results

Neurocrine Biosciences Q3 2026 Results: Net Income $206M, Down 1.4% YoY

Neurocrine Biosciences reported significant growth for the third quarter of 2026, with net product sales increasing to $1.12 billion compared to $789.9 million in the prior year. While net income for the quarter remained relatively flat at $206.5 million due to higher operating expenses and investment losses, the company's nine-month net income grew substantially to $548.8 million.

Key figure
Net income $206M · -1.4% YoY
4:11 PM ET 8-K
Financial Results

Neurocrine Biosciences Financial Results

Neurocrine Biosciences reported third-quarter 2026 total revenue of $1.1 billion, a 41% increase year-over-year, driven by strong sales of INGREZZA and CRENESSITY. The company raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion.

Term
Q3 2026

“Our third quarter performance marks another important milestone in Neurocrine’s evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines. This continued growth reinforces the strength of our strategy and expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company.”

Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences
4:21 PM ET 8-K
Leadership Change

Neurocrine Biosciences Leadership Change

Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer, succeeding Sanjay Keswani, M.D., effective September 28, 2026. Dr. Roberts will receive an annual base salary of $825,000, a 60% target bonus, and equity grants totaling approximately $1.25 million in target value. Dr. Keswani's departure was described as a mutual agreement, and he will receive severance benefits under the company's existing executive plan.

Counterparty
Eiry W. Roberts, M.D.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.